Ipca Laboratories Moat Analysis: Score & Risks
Ipca Laboratories Ltd.
A first-pass moat teardown of Ipca Laboratories Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Cost Advantage. Provisional, single-pass evidence.
Ipca Laboratories Ltd. scores 4.92 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“Indian pharmaceutical industry benefits from cost competitiveness driven by backward integration, lower labour cost, economies of scale and efficient manufacturing processes.”
“The impact of NLEM product price reduction in Q4 FY23 of around 16% on price control segment was partially offset with WIP based price increase taken in Q1 FY24.”
“we are increasing our field force size from 4800 medical reps to almost around 6000 medical reps”
“These manufacturing sites are currently awaiting re-inspection by US FDA.”
“Withdrawal of exemptions given to certain APIs and formulations manufactured by the Company from the import alert by US FDA in June 2017 as well as Global Fund not sourcing the anti-malarial formulations manufactured by the Company impacted the Company's international business growth during the financial year.”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 509 Indian companies we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion